CalciMedica is trading at $0.65, up +6.02%, as a 2.27% pre-market gain in biotech ETF XBI points to sector-wide risk appetite.

  • No new company-specific announcement was identified for August 20, 2026.
  • Recent shareholder proposals include a potential 1-for-2 to 1-for-10 reverse split and warrant issuances.
  • These proposals were previously disclosed and are not a fresh catalyst.